Patient Care

09.26.22

Third-party VST early after allo-HSCT

by ASTCT Science Highlights

09.15.22

Higher doses of tisagenlecleucel associated with improved outcomes

by ASTCT Science Highlights

09.06.22

Mechanisms of Effector Development in CAR-T Products

by ASTCT Science Highlights

08.30.22

Stem Cell Boost After CAR-T Cell Therapy

by ASTCT Science Highlights

08.16.22

Novel Hinge Domains in CAR-T Design

by ASTCT Science Highlights

$Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up$

08.02.22

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

by ASTCT Science Highlights

07.28.22

Single-Cell Antigen-Specific Landscape of CAR T Infusion Product Identifies Determinants of CD19-Positive Relapse in Patients with ALL

by ASTCT Science Highlights

07.26.22

Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL

by ASTCT Science Highlights

06.21.22

Complex Genomic Features Underlying CAR T-Cell Failures in Lymphoma

by ASTCT Science Highlights

THANK YOU TO OUR SPONSORS